Navigation Links
NeuroQuest Close to Validation Trial for Biomarker Platform in Diagnosis of Alzheimer's
Date:12/10/2012

TEL AVIV, Israel, December 10, 2012 /PRNewswire/ --

NeuroQuest, a company of the Trendlines Group's Misgav Venture Accelerator is moving quickly towards an important validation trial for novel blood-based immune biomarkers for the diagnosis of Alzheimer's disease. The company's biomarker platform for neurodegenerative diseases is based on the research of Prof. Michal Schwartz, Chair of Neuroimmunology at the Weizmann Institute of Science who pioneered the concept of Protective AutoImmunity. The trial is a follow-up to the preliminary human trial performed at Sheba, Rambam, and Abarbanel Medical Centers in Israel and Methodist Neurological Institute in Houston, Texas which demonstrated up to 85% diagnostic accuracy and specificity in AD and ALS patients in mild to moderate stages versus healthy controls. The success of the validation trial would present a new approach for a simple, inexpensive, and early diagnosis of Alzheimer's disease. Successful results may lead to new therapeutic targets for this disease, opening new directions to an industry searching for novel approaches to combat AD, given the recent failures of several Phase III trials for therapeutics targeting Beta-Amyloid reduction.

Dr. Jacobo Mintzer, Co-Director of Alzheimer's Research & Clinical Programs of the Medical University of South Carolina, has joined the company as its new VP of Clinical affairs to leverage his experience in over 200 Alzheimer's-related clinical trials. NeuroQuest has also announced a new partnership with the Harvard Clinical Research Institute and their Senior Director of Clinical Program Management, Dr. Jennifer Buell. Together the teams are gearing up for a 150-200 patients clinical trial at MUSC, Harvard, and other medical centers to validate the company's novel immune-based biomarkers for Alzheimer's Disease.

The company has confirmed financing totaling $500,000 led by InterTech Group, headed by Jonathan Zucker, and the Maryland/Israel Trendlines Fund. The company is also in serious discussions with the South Carolina Research Authority (SCRA) about a grant to support opening a US development center in Charleston, SC as the base of its clinical and regulatory work. Many of these developments were put into motion following a 2011 American Israel Chamber of Commerce - South East's (AICC-SE) delegation from South Carolina headed by Tom Glaser. Glaser's group, returned to Israel and Misgav again this week to celebrate and investigate additional opportunities for collaboration and investment.

Contact:
Efrat Kaduri
Ofir Shpigel Media and Public Relations
+972-4-9535030
Efrat@ofirpr.co.il


'/>"/>
SOURCE NeuroQuest
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Wright Therapy Products, Inc. Closes $3 million Financing Round
2. Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
3. Edison Pharmaceuticals Closes $20M Series F Financing
4. MabVax Therapeutics Closes $5.25 Million Financing with Numoda Capital Innovations, Burrill Capital Fund IV, and RTP Venture Fund
5. DenTech China 2012 Closed with Success
6. Agnitio Sets Up Asia HQ in Shanghai and is the First to Bring the Combined Closed Loops of Marketing and E-Learning to the Pharmaceutical Industry
7. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
8. Novelos Therapeutics Closes $2 Million Private Placement
9. ClosedWon Launches QuickQuote at Dreamforce 2012 on Salesforce.coms AppExchange, the Worlds Most Popular Cloud Marketplace for Social Apps for Business
10. RxAnte Closes Series A Financing
11. Aethlon Medical Discloses MD Anderson Cancer Center Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
Breaking Medicine News(10 mins):